NEW YORK, December 23, 2016 /PRNewswire/ --
This morning, Stock-Callers.com draws investors' attention to the following Medical Instruments and Supplies equities: The Cooper Cos. Inc. (NYSE: COO), Insulet Corp. (NASDAQ: PODD), Glaukos Corp. (NYSE: GKOS), and C. R. Bard Inc. (NYSE: BCR). These companies belong to the Healthcare sector which was slightly higher in late trade on Thursday, December 22nd, 2016. As per an article on NASDAQ, the NYSE Health Care Index climbed about 0.1%, while shares of health care companies in the S&P 500 rose 0.1% as a group. Register now and get full and free access to our downloadable research reports on these stocks at:
Pleasanton, California headquartered The Cooper Cos. Inc.'s stock finished Thursday's session 0.87% lower at $173.10. A total volume of 764,855 shares was traded, which was above their three months average volume of 717,850 shares. The Company's shares have advanced 1.82% in the past one month and 29.04% on an YTD basis. The stock is trading 1.54% above its 200-day moving average. Additionally, shares of The Cooper Cos., which operates as a medical device company worldwide, have a Relative Strength Index (RSI) of 50.27.
On December 12th, 2016, research firm Wells Fargo upgraded the Company's stock rating from 'Market Perform' to 'Outperform'.
On December 21st, 2016, Cooper announced that it will hold its next annual meeting of stockholders on March 13th, 2017. Stockholders of record as of the close of business on January 17th, 2017 will be eligible to vote on matters presented in the Company's proxy statement, including electing its slate of directors. Access our complete research report on COO for free at:
On Thursday, shares in Billerica, Massachusetts headquartered Insulet Corp. recorded a trading volume of 348,673 shares. The stock ended the session 0.59% lower at $37.36. The Company's shares have advanced 0.65% in the last one month. The stock is trading 1.39% above its 50-day moving average and 5.01% above its 200-day moving average. Moreover, shares of Insulet, which develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the US, have an RSI of 50.87.
As per a SEC filing dated December 20th, 2016, Insulet agreed to purchase from 100 Nagog Park Limited Partnership ("NPLP"), certain property located at 100 Nagog Park in Acton, Massachusetts on December 16th, 2016. The Property consists of approximately 25 acres of land and all buildings, structures, parking areas, and improvements located thereon, with approximately 195,000 square feet of space. Pursuant to the Agreement, and upon the terms and subject to the conditions thereof, the Company has agreed to pay NPLP a total purchase price for the Property of $9,250,000, subject to certain adjustments for taxes and utility charges. The complimentary research report on PODD can be downloaded at:
Shares in Laguna Hills, California headquartered Glaukos Corp. closed the day 0.44% higher at $33.93. The stock recorded a trading volume of 313,656 shares. The Company's shares have gained 3.70% in the last one month and 37.42% on an YTD basis. The stock is trading 0.89% and 17.15% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Glaukos, which develops and commercializes products and procedures designed for the treatment of glaucoma, have an RSI of 52.44.
On December 12th, 2016, Glaukos announced that a study published recently in the Journal of Glaucoma showed that a single iStent® Trabecular Micro-Bypass Stent significantly reduced intraocular pressure (IOP) when implanted as a standalone procedure in pseudophakic eyes with open-angle glaucoma. In this retrospective, consecutive case series, researchers from the University of South Dakota Sanford School of Medicine and Sioux Falls-based Vance Thomson Vision evaluated iStent procedure outcomes in 42 pseudophakic eyes with preoperative mean IOP of 20.26 mm Hg. In 21 eyes followed for two years, mean medicated IOP decreased 6.64 mm Hg to 13.62 mm Hg, or 33%. Register for free on Stock-Callers.com and get access to the latest PDF format report on GKOS at:
C. R. Bard
At the close, shares in Murray Hill, New Jersey headquartered C. R. Bard Inc. finished 0.46% higher at $220.68. The stock recorded a trading volume of 431,216 shares. The Company's shares have advanced 5.69% in the last one month and 17.05% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 2.24% and 1.34%, respectively. Furthermore, shares of C. R. Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have an RSI of 58.22.
On December 14th, 2016, C. R. Bard's Board of Directors declared a regular quarterly dividend of $0.26 per share on Bard's common stock. The dividend is payable on February 3rd, 2017 to shareholders of record at the close of business on January 23rd, 2017. Download your free research report on BCR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA